Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Rohit Thummalapalli; Biagio Ricciuti; Chaitanya Bandlamudi; Daniel M. Muldoon; Hira Rizvi; Arielle Elkrief; Jia Luo; Joao V. Alessi; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Lingzhi Hong; Jianjun Zhang; John V. Heymach; Don L. Gibbons; Andrew J. Plodkowski; Vignesh Ravichandran; Mark T.A. Donoghue; Chad Vanderbilt; Marc Ladanyi; Charles M. Rudin; Mark G. Kris; Gregory J. Riely; Jamie E. Chaft; Matthew D. Hellmann; Natalie I. Vokes; Mark M. Awad; Adam J. Schoenfeld

doi:10.1158/1078-0432.27033031

Abstract

Kaplan-Meier curves of (A) overall survival (OS) and (B) progression-free survival (PFS) among patients with complete response (CR) in the combined cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thummalapalli et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752397c https://doi.org/10.1158/1078-0432.27033031

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers